Ignacio Varela

Ignacio Varela

Auto-generated profile, based on publicly available information

Ignacio Varela

Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Universidad de Cantabria-CSIC, Santander, Spain

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2012 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
MGMarco Gerlinger
Marco Gerlinger
ARAndrew J. Rowan
Andrew J. Rowan
SHStuart Horswell
Stuart Horswell
JLJames Larkin
James Larkin
DEDavid Endesfelder
David Endesfelder
CSCharles Swanton
Charles Swanton
Intratumor heterogeneity may foster tumor evolution and adaptation and hinder personalized-medicine strategies that depend on results from single tumor-biopsy samples. To examine intratumor heterogeneity, we performed exome sequencing, chromosome aberration analysis, and ploidy profiling on multiple spatially separated samples obtained from primary renal carcinomas and associated metastatic sites. We characterized the consequences of intratumor heterogeneity using immunohistochemical analysis, mutation functional analysis, and profiling of messenger RNA expression. Phylogenetic reconstruction revealed branched evolutionary tumor growth, with 63 to 69% of all somatic mutations not detectable across every tumor region. Intratumor heterogeneity was observed for a mutation within an autoinhibitory domain of the mammalian target of rapamycin (mTOR) kinase, correlating with S6 and 4EBP phosphorylation in vivo and constitutive activation of mTOR kinase activity in vitro. Mutational intratumor heterogeneity was seen for multiple tumor-suppressor genes converging on loss of function; SETD2, PTEN, and KDM5C underwent multiple distinct and spatially separated inactivating mutations within a single tumor, suggesting convergent phenotypic evolution. Gene-expression signatures of good and poor prognosis were detected in different regions of the same tumor. Allelic composition and ploidy profiling analysis revealed extensive intratumor heterogeneity, with 26 of 30 tumor samples from four tumors harboring divergent allelic-imbalance profiles and with ploidy heterogeneity in two of four tumors. Intratumor heterogeneity can lead to underestimation of the tumor genomics landscape portrayed from single tumor-biopsy samples and may present major challenges to personalized-medicine and biomarker development. Intratumor heterogeneity, associated with heterogeneous protein function, may foster tumor adaptation and therapeutic failure through Darwinian selection. (Funded by the Medical Research Council and others.)

1 January 2011 in Cell
Verified
Journal Article
Open access
PSPhilip J. Stephens
Philip J. Stephens
CGChris D. Greenman
Chris D. Greenman
BFBeiyuan Fu
Beiyuan Fu
FYFengtang Yang
Fengtang Yang
GBGraham R. Bignell
Graham R. Bignell
PCPeter J. Campbell
Peter J. Campbell
Cancer is driven by somatically acquired point mutations and chromosomal rearrangements, conventionally thought to accumulate gradually over time. Using next-generation sequencing, we characterize a phenomenon, which we term chromothripsis, whereby tens to hundreds of genomic rearrangements occur in a one-off cellular crisis. Rearrangements involving one or a few chromosomes crisscross back and forth across involved regions, generating frequent oscillations between two copy number states. These genomic hallmarks are highly improbable if rearrangements accumulate over time and instead imply that nearly all occur during a single cellular catastrophe. The stamp of chromothripsis can be seen in at least 2%-3% of all cancers, across many subtypes, and is present in ∼25% of bone cancers. We find that one, or indeed more than one, cancer-causing lesion can emerge out of the genomic crisis. This phenomenon has important implications for the origins of genomic remodeling and temporal emergence of cancer.

1 May 2012 in Cell
Verified
Journal Article
Open access
SNSerena Nik-Zainal
Serena Nik-Zainal
LALudmil B. Alexandrov
Ludmil B. Alexandrov
DWDavid Wedge
David Wedge
PLPeter Van Loo
Peter Van Loo
CGChristopher D. Greenman
Christopher D. Greenman
MSMichael R. Stratton
Michael R. Stratton
All cancers carry somatic mutations. The patterns of mutation in cancer genomes reflect the DNA damage and repair processes to which cancer cells and their precursors have been exposed. To explore these mechanisms further, we generated catalogs of somatic mutation from 21 breast cancers and applied mathematical methods to extract mutational signatures of the underlying processes. Multiple distinct single- and double-nucleotide substitution signatures were discernible. Cancers with BRCA1 or BRCA2 mutations exhibited a characteristic combination of substitution mutation signatures and a distinctive profile of deletions. Complex relationships between somatic mutation prevalence and transcription were detected. A remarkable phenomenon of localized hypermutation, termed "kataegis," was observed. Regions of kataegis differed between cancers but usually colocalized with somatic rearrangements. Base substitutions in these regions were almost exclusively of cytosine at TpC dinucleotides. The mechanisms underlying most of these mutational signatures are unknown. However, a role for the APOBEC family of cytidine deaminases is proposed.

16 May 2012 in Nature
Verified
Journal Article
Closed access
PDF file
T(The Oslo Breast Cancer Consortium (OSBREAC)
The Oslo Breast Cancer Consortium (OSBREAC)
PSPhilip J. Stephens
Philip J. Stephens
PTPatrick S. Tarpey
Patrick S. Tarpey
HDHelen Davies
Helen Davies
PLPeter Van Loo
Peter Van Loo
MSMichael R. Stratton
Michael R. Stratton

16 December 2009 in Nature
Verified
Journal Article
Open access
PDF file
EPErin D. Pleasance
Erin D. Pleasance
RCR. Keira Cheetham
R. Keira Cheetham
PSPhilip J. Stephens
Philip J. Stephens
DMDavid J. McBride
David J. McBride
SHSean J. Humphray
Sean J. Humphray
MSMichael R. Stratton
Michael R. Stratton
All cancers carry somatic mutations. A subset of these somatic alterations, termed driver mutations, confer selective growth advantage and are implicated in cancer development, whereas the remainder are passengers. Here we have sequenced the genomes of a malignant melanoma and a lymphoblastoid cell line from the same person, providing the first comprehensive catalogue of somatic mutations from an individual cancer. The catalogue provides remarkable insights into the forces that have shaped this cancer genome. The dominant mutational signature reflects DNA damage due to ultraviolet light exposure, a known risk factor for malignant melanoma, whereas the uneven distribution of mutations across the genome, with a lower prevalence in gene footprints, indicates that DNA repair has been preferentially deployed towards transcribed regions. The results illustrate the power of a cancer genome sequence to reveal traces of the DNA damage, repair, mutation and selection processes that were operative years before the cancer became symptomatic.

1 May 2012 in Cell
Verified
Journal Article
Open access
SNSerena Nik-Zainal
Serena Nik-Zainal
PLPeter Van Loo
Peter Van Loo
DWDavid Wedge
David Wedge
LALudmil B. Alexandrov
Ludmil B. Alexandrov
CGChristopher D. Greenman
Christopher D. Greenman
PCPeter J. Campbell
Peter J. Campbell
Cancer evolves dynamically as clonal expansions supersede one another driven by shifting selective pressures, mutational processes, and disrupted cancer genes. These processes mark the genome, such that a cancer's life history is encrypted in the somatic mutations present. We developed algorithms to decipher this narrative and applied them to 21 breast cancers. Mutational processes evolve across a cancer's lifespan, with many emerging late but contributing extensive genetic variation. Subclonal diversification is prominent, and most mutations are found in just a fraction of tumor cells. Every tumor has a dominant subclonal lineage, representing more than 50% of tumor cells. Minimal expansion of these subclones occurs until many hundreds to thousands of mutations have accumulated, implying the existence of long-lived, quiescent cell lineages capable of substantial proliferation upon acquisition of enabling genomic changes. Expansion of the dominant subclone to an appreciable mass may therefore represent the final rate-limiting step in a breast cancer's development, triggering diagnosis.